Kiniksa Pharmaceuticals International (KNSA) Competitors $32.15 -0.96 (-2.90%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$32.16 +0.01 (+0.02%) As of 08/8/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KNSA vs. RGC, ELAN, RVMD, GRFS, TGTX, NUVL, CRSP, RYTM, LNTH, and AXSMShould you be buying Kiniksa Pharmaceuticals International stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals International include Regencell Bioscience (RGC), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), CRISPR Therapeutics (CRSP), Rhythm Pharmaceuticals (RYTM), Lantheus (LNTH), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals International vs. Its Competitors Regencell Bioscience Elanco Animal Health Revolution Medicines Grifols TG Therapeutics Nuvalent CRISPR Therapeutics Rhythm Pharmaceuticals Lantheus Axsome Therapeutics Regencell Bioscience (NASDAQ:RGC) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability. Do analysts prefer RGC or KNSA? Kiniksa Pharmaceuticals International has a consensus price target of $41.17, suggesting a potential upside of 28.05%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher probable upside, analysts plainly believe Kiniksa Pharmaceuticals International is more favorable than Regencell Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, RGC or KNSA? Regencell Bioscience has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Which has better earnings & valuation, RGC or KNSA? Regencell Bioscience has higher earnings, but lower revenue than Kiniksa Pharmaceuticals International. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegencell BioscienceN/AN/A-$4.30MN/AN/AKiniksa Pharmaceuticals International$423.24M5.54-$43.19M$0.04803.75 Is RGC or KNSA more profitable? Kiniksa Pharmaceuticals International has a net margin of 0.90% compared to Regencell Bioscience's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 1.05% beat Regencell Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Regencell BioscienceN/A N/A N/A Kiniksa Pharmaceuticals International 0.90%1.05%0.80% Does the media favor RGC or KNSA? In the previous week, Kiniksa Pharmaceuticals International had 14 more articles in the media than Regencell Bioscience. MarketBeat recorded 15 mentions for Kiniksa Pharmaceuticals International and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.94 beat Kiniksa Pharmaceuticals International's score of 0.71 indicating that Regencell Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Kiniksa Pharmaceuticals International 7 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in RGC or KNSA? 0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Comparatively, 53.5% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryKiniksa Pharmaceuticals International beats Regencell Bioscience on 10 of the 13 factors compared between the two stocks. Get Kiniksa Pharmaceuticals International News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa Pharmaceuticals InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.42B$2.97B$5.44B$9.61BDividend YieldN/A2.46%4.61%4.14%P/E Ratio803.9516.9029.7524.84Price / Sales5.54313.57449.1298.65Price / CashN/A41.8536.4258.36Price / Book4.747.318.185.64Net Income-$43.19M-$54.43M$3.26B$265.68M7 Day Performance0.53%0.00%6.88%4.95%1 Month Performance11.63%1.33%1.00%0.83%1 Year Performance27.73%8.64%28.85%22.18% Kiniksa Pharmaceuticals International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals International3.4262 of 5 stars$32.15-2.9%$41.17+28.0%+29.8%$2.42B$423.24M803.95220News CoverageInsider TradeRGCRegencell Bioscience0.2102 of 5 stars$13.80-8.3%N/AN/A$7.44BN/A0.0010Positive NewsELANElanco Animal Health3.3282 of 5 stars$14.59-2.2%$16.17+10.8%+27.9%$7.41B$4.43B19.729,000Trending NewsEarnings ReportAnalyst ForecastRVMDRevolution Medicines4.4256 of 5 stars$37.26-1.7%$68.91+84.9%-16.6%$7.06B$11.58M-9.32250News CoverageEarnings ReportAnalyst ForecastGRFSGrifols3.2576 of 5 stars$10.09-0.1%$10.30+2.1%+44.4%$6.94B$7.81B8.6223,822Positive NewsAnalyst ForecastTGTXTG Therapeutics4.0004 of 5 stars$35.99-2.5%$43.80+21.7%+33.3%$5.86B$329M149.96290Trending NewsEarnings ReportAnalyst RevisionNUVLNuvalent3.1176 of 5 stars$81.94+0.7%$119.60+46.0%+5.5%$5.85BN/A-18.6740News CoverageUpcoming EarningsInsider TradeCRSPCRISPR Therapeutics3.6684 of 5 stars$63.75-1.6%$71.31+11.9%+14.9%$5.59B$37.31M-14.10460Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionRYTMRhythm Pharmaceuticals3.9964 of 5 stars$85.68-0.9%$91.93+7.3%+100.5%$5.50B$130.13M-30.49140Earnings ReportAnalyst ForecastAnalyst RevisionLNTHLantheus4.6076 of 5 stars$72.41-0.7%$131.20+81.2%-41.2%$5.05B$1.53B20.57700Trending NewsEarnings ReportAnalyst ForecastAXSMAxsome Therapeutics4.7957 of 5 stars$100.39-0.4%$172.33+71.7%+23.3%$4.96B$385.69M-17.40380Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Regencell Bioscience Alternatives Elanco Animal Health Alternatives Revolution Medicines Alternatives Grifols Alternatives TG Therapeutics Alternatives Nuvalent Alternatives CRISPR Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives Lantheus Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KNSA) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft....Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals International, plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KNSA Stock Alerts